GLTO 241220 5.00C (GLTO241220C5000) Stock Options, News & Quotes

0.00
0.000.00%

15min DelayClose Nov 15 09:30 ET

0.00High0.00Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Jaguar8

Oct 7 08:25

NEWS

$Galecto (GLTO.US)$
Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines
• Galecto will focus on cancer and liver disease, leveraging existing clinical stage asset GB1211
• Bolsters pipeline by obtaining global rights to BRM-1420, a novel dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of acute myeloid leukemia (AML)
• BRM-1420 has the potential for enhanced clinical effectivenes...

Trytosaveabit

Sep 18 05:09

Update

$Galecto (GLTO.US)$ Galecto Has Regained Compliance With The Minimum Bid Price Requirement In Nasdaq Listing Rule

Jaguar8

May 1 15:02

$Galecto (GLTO.US)$
NEWS
Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab
Galecto, Inc. announced the enrollment of the first patient in an investigator-initiated Phase 2 trial to evaluate GB1211, a galectin-3 inhibitor, in combination with pembrolizumab for metastatic melanoma and head and neck squamous cell carcinoma. Galecto aims to explore GB1211's potential to enhance the effectiveness of pembrolizumab in various can...

oh wow

$Galecto (GLTO.US)$
@FiReBiTriXiE @jimmy the trader @MangoXXX @PYUN970IHaveChosen @Ripper @Rivera @Trytosaveabit @VinylEagle @Wind_Storm @8 Seconds